<div id="readability-page-1"><div><p>BofAS issued a report stating that Zai Lab (09688.HK)<span> </span><span> -0.060 (-0.344%)  </span> <span> Short selling $23.80M; Ratio 21.439%  </span> 's total sales of sample drugs in February amounted to RMB112.7 million, representing a YoY increase of 13.2%. Sales of Niraparib narrowed its YoY decline to 2%, improving from the 16.3% drop in January, with revenue reaching RMB49.6 million. Monthly sales of omadacycline and ripretinib were RMB35.1 million and RMB9.5 million, respectively, marking YoY growth of 45.5% and 32.6%. Sales of efgartigimod alfa increased 4.9% YoY but declined 40.9% MoM.</p><p>Due to positive progress in ZL-1310 (DLL3 ADC), the broker raised its probability of success (POS) from 75% to 80%. Accordingly, it lifted its 2028 revenue forecast by 2% and also raised its long-term revenue projections. BofAS increased its US share TP for Zai Lab (ZLAB.US)<span> </span>  <span> </span>   from USD21.8 to USD24, and its HK share TP from HKD16.9 to HKD18.6. The Neutral rating was reiterated, as positive pipeline developments are offset by relatively weak performance of core products. (ha/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-27 16:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)</p></div><p>This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.</p></div>

ZLAB

09688

<p>BofAS has raised its target price for Zai Labto HKD18.6 while maintaining a Neutral rating. The report highlights a 13.2% YoY increase in total sales of sample drugs, reaching RMB112.7 million in February. Notable sales include Niraparib, which saw a reduced YoY decline, and significant growth in omadacycline and ripretinib. The broker also increased its probability of success for ZL-1310 from 75% to 80%, leading to a 2% rise in the 2028 revenue forecast. The US share target price was raised from USD21.8 to USD24.</p>

- BofAS reported Zai Lab's total sales of sample drugs in February reached RMB112.7 million, a 13.2% year-over-year increase.  
- Sales of Niraparib improved, with revenue of RMB49.6 million and a YoY decline narrowed to 2%.  
- The broker raised Zai Lab's long-term revenue projections and share price targets, maintaining a Neutral rating due to mixed product performance.

AASTOCKS News

Zai Lab

ZAI LAB

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Guotai CSI Bio-medicine ETF

ALPS Medical Breakthrough

VG Health

ChinaAMC CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

VanEck Biotech ETF

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

E Fund CSI Biotechnology Theme ETF

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

iShares US Pharma

Ark Genomic Revolution ETF

Bank of America

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

BofAS Raises Zai Lab  TP to HKD18.6, Rating Neutral